ONCS
Income statement / Annual
Last year (2022), OncoSec Medical Incorporated's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2022, OncoSec Medical Incorporated's net income was -$34.18 M.
See OncoSec Medical Incorporated,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
| Period Ended |
07/31/2022 |
07/31/2021 |
07/31/2020 |
07/31/2019 |
07/31/2018 |
07/31/2017 |
07/31/2016 |
07/31/2015 |
07/31/2014 |
07/31/2013 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$25.82 M
|
$34.10 M
|
$25.10 M
|
$18.45 M
|
$17.42 M
|
$11.95 M
|
$14.74 M
|
$13.13 M
|
$5.80 M
|
$3.16 M
|
| General & Administrative Expenses |
$11.19 M
|
$14.28 M
|
$18.31 M
|
$11.97 M
|
$18.69 M
|
$9.50 M
|
$12.14 M
|
$8.11 M
|
$6.15 M
|
$3.91 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$11.19 M
|
$14.28 M
|
$18.31 M
|
$11.97 M
|
$18.69 M
|
$9.50 M
|
$12.14 M
|
$8.11 M
|
$6.15 M
|
$3.91 M
|
| Other Expenses |
$28.86 K
|
-$704.00
|
$185.05 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$37.01 M
|
$48.38 M
|
$43.41 M
|
$30.42 M
|
$36.11 M
|
$21.45 M
|
$26.89 M
|
$21.24 M
|
$11.95 M
|
$7.06 M
|
| Cost And Expenses |
$37.01 M
|
$48.38 M
|
$43.41 M
|
$30.42 M
|
$36.11 M
|
$21.45 M
|
$26.89 M
|
$21.24 M
|
$11.95 M
|
$7.06 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$20.93 K
|
$15.86 K
|
$5.11 K
|
$3.81 K
|
$6.37 M
|
$0.00
|
$0.00
|
$0.00
|
$20.68 K
|
$83.22 K
|
| Depreciation & Amortization |
$1.10 M
|
$1.08 M
|
$1.18 M
|
$683.75 K
|
$3.67 M
|
$379.99 K
|
$355.58 K
|
$664.60 K
|
$780.11 K
|
$736.88 K
|
| EBITDA |
-$36.40 M |
-$46.49 M |
-$42.23 M |
-$29.73 M |
-$32.43 M |
-$21.07 M |
-$26.89 T |
-$21.24 B |
-$11.95 B |
-$7.06 B |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$501.72 K
|
$800.14 K
|
$283.07 K
|
$141.92 K
|
-$3.03 M
|
$0.00
|
$0.00
|
$0.00
|
-$20.68 K
|
-$83.22 K
|
| Income Before Tax |
-$37.51 M
|
-$47.58 M
|
-$43.13 M
|
-$30.27 M
|
-$39.14 M
|
-$21.45 M
|
-$26.89 M
|
-$21.24 M
|
-$11.97 M
|
-$7.15 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
-$3.33 M
|
-$2.41 M
|
-$872.59 K
|
$1.30 K
|
$680.00
|
$1.39 K
|
$2.46 K
|
$1.97 K
|
$41.77 K
|
$2.00 K
|
| Net Income |
-$34.18 M
|
-$45.17 M
|
-$42.25 M
|
-$30.28 M
|
-$39.14 M
|
-$21.45 M
|
-$26.89 M
|
-$21.24 M
|
-$12.01 M
|
-$7.15 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-19.13 |
-30.2 |
-56.22 |
-94.43 |
-214.59 |
-233.73 |
-358.2 |
-367.73 |
-277.38 |
-295.25 |
| EPS Diluted |
-19.13 |
-30.2 |
-56.22 |
-94.43 |
-214.59 |
-233.73 |
-358.2 |
-367.73 |
-277.38 |
-295.25 |
| Weighted Average Shares Out |
$1.79 M
|
$1.50 M
|
$751.57 K
|
$320.60 K
|
$182.38 K
|
$91.77 K
|
$75.07 K
|
$57.77 K
|
$43.31 K
|
$24.22 K
|
| Weighted Average Shares Out Diluted |
$1.79 M
|
$1.50 M
|
$751.57 K
|
$320.60 K
|
$182.38 K
|
$91.77 K
|
$75.07 K
|
$57.77 K
|
$43.31 K
|
$24.22 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
